MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

Abstract Background Inhibition of cyclin-dependent kinase 9 (CDK9), a novel epigenetic target in cancer, can reactivate epigenetically silenced genes in cancer by dephosphorylating the SWI/SNF chromatin remodeler BRG1. Here, we characterized the anti-tumor efficacy of MC180295, a newly developed CDK...

Full description

Bibliographic Details
Main Authors: Hanghang Zhang, Chen Huang, John Gordon, Sijia Yu, George Morton, Wayne Childers, Magid Abou-Gharbia, Yi Zhang, Jaroslav Jelinek, Jean-Pierre J. Issa
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Clinical Epigenetics
Subjects:
Epigenetic therapy
CDK9
Immunosensitization
MC180380
Anti-tumoral effects
Online Access:https://doi.org/10.1186/s13148-023-01617-3

Internet

https://doi.org/10.1186/s13148-023-01617-3

Similar Items